Baird Maintains Outperform on Alto Neuroscience, Lowers Price Target to $36

Alto Neuroscience, Inc.

Alto Neuroscience, Inc.

ANRO

0.00

Baird analyst Brian Skorney maintains Alto Neuroscience (NYSE: ANRO) with a Outperform and lowers the price target from $38 to $36.